Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126949321 | 12694932 | 1 | I | 2016 | 20160502 | 20160829 | 20160829 | PER | US-ASTRAZENECA-2016SE48815 | ASTRAZENECA | 55.00 | YR | F | Y | 0.00000 | 20160829 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126949321 | 12694932 | 1 | PS | SEROQUEL XR | QUETIAPINE FUMARATE | 1 | Oral | 22047 | PROLONGED-RELEASE TABLET | ||||||||||
| 126949321 | 12694932 | 2 | SS | SEROQUEL XR | QUETIAPINE FUMARATE | 1 | Oral | 450.0MG UNKNOWN | 22047 | 450 | MG | TABLET | |||||||
| 126949321 | 12694932 | 3 | SS | SEROQUEL XR | QUETIAPINE FUMARATE | 1 | Oral | 50.0MG UNKNOWN | 22047 | 50 | MG | TABLET | |||||||
| 126949321 | 12694932 | 4 | SS | REXULTI | BREXPIPRAZOLE | 1 | Oral | 0.5 MG | U | U | 0 | TABLET | |||||||
| 126949321 | 12694932 | 5 | SS | REXULTI | BREXPIPRAZOLE | 1 | Oral | 0.5 MG EVERY DAY | U | U | 0 | TABLET | |||||||
| 126949321 | 12694932 | 6 | SS | REXULTI | BREXPIPRAZOLE | 1 | Oral | 1 MG 1 WEEK | U | U | 0 | TABLET | |||||||
| 126949321 | 12694932 | 7 | SS | REXULTI | BREXPIPRAZOLE | 1 | Oral | 2 MG FOR 1 WEEK | U | U | 0 | TABLET | |||||||
| 126949321 | 12694932 | 8 | C | ABILIFY | ARIPIPRAZOLE | 1 | 0 | ||||||||||||
| 126949321 | 12694932 | 9 | C | NAPROXEN. | NAPROXEN | 1 | 0 | ||||||||||||
| 126949321 | 12694932 | 10 | C | ZIPRASIDONE. | ZIPRASIDONE | 1 | 0 | ||||||||||||
| 126949321 | 12694932 | 11 | C | DIVALPROEX SODIUM. | DIVALPROEX SODIUM | 1 | 0 | ||||||||||||
| 126949321 | 12694932 | 12 | C | OXCARBAZEPINE. | OXCARBAZEPINE | 1 | 0 | ||||||||||||
| 126949321 | 12694932 | 13 | C | DIOVAN | VALSARTAN | 1 | 0 | ||||||||||||
| 126949321 | 12694932 | 14 | C | PROPRANOLOL | PROPRANOLOLPROPRANOLOL HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 126949321 | 12694932 | 15 | C | ESTRADIOL. | ESTRADIOL | 1 | TOPICAL | 0 | |||||||||||
| 126949321 | 12694932 | 16 | C | ESTRADIOL. | ESTRADIOL | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126949321 | 12694932 | 4 | Affective disorder |
| 126949321 | 12694932 | 5 | Affective disorder |
| 126949321 | 12694932 | 6 | Affective disorder |
| 126949321 | 12694932 | 7 | Affective disorder |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126949321 | 12694932 | Blood glucose increased | |
| 126949321 | 12694932 | Blood pressure increased | |
| 126949321 | 12694932 | Off label use | |
| 126949321 | 12694932 | Palpitations | |
| 126949321 | 12694932 | Product use issue | |
| 126949321 | 12694932 | Weight increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126949321 | 12694932 | 2 | 20160802 | 0 | ||
| 126949321 | 12694932 | 4 | 20160329 | 0 | ||
| 126949321 | 12694932 | 5 | 20160802 | 0 | ||
| 126949321 | 12694932 | 8 | 2009 | 0 |